...der scheint aber hier bei einigen nicht gut gelitten.
Egal, was mich hier ganz entspannt "shareholder" sein läßt, sind die Aussagen des Unternehmens beim letzten Earnings Conference Call, am 17.12.2015:
"...While our stock has been materially negligibly impacted, our cash position is relatively strong. We ended fiscal year 2015 with approximately $40 million. As a result, we have received a number of inbound expressions of interest from companies pursuing strategic alternatives for their assets. We have therefore initiated a review to indentify strategic alternatives that will be in the best interest of our shareholders. Commensurate to this review, we have decided to suspend our BIOD-531 clinical study, including study 3-250 and 3-157 to take other measures and take other measures to preserve cash. While a difficult decision, we believe itoffers the best opportunity to maximize shareholder value from our clinical assets and cash resources. I look forward to being able our investors on the process in the coming months...."
seekingalpha.com/article/...rnings-call-transcript?part=single